Thursday, November 02, 2017 7:51:00 AM
Recent TEVA News
- Teva Announces Collaboration to Commercialize Formycon’s Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel • GlobeNewswire Inc. • 01/13/2025 06:00:00 AM
- Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States • GlobeNewswire Inc. • 01/10/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/26/2024 09:02:21 PM
- Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 12/23/2024 09:30:00 PM
- Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025 • GlobeNewswire Inc. • 12/20/2024 09:30:00 PM
- Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease • GlobeNewswire Inc. • 12/17/2024 12:30:00 PM
- Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients • GlobeNewswire Inc. • 12/11/2024 01:00:00 PM
- Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan • GlobeNewswire Inc. • 12/05/2024 11:00:00 PM
- Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial • GlobeNewswire Inc. • 12/04/2024 07:00:00 AM
- Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference • GlobeNewswire Inc. • 11/25/2024 11:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2024 09:04:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/20/2024 04:39:01 PM
- Teva to Present at the Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/08/2024 09:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2024 09:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2024 12:00:13 PM
- Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS • GlobeNewswire Inc. • 11/06/2024 12:00:00 PM
- U.S. Index Futures Surge on Trump Victory Prospects; Commodities Slide Amid Dollar Strength • IH Market News • 11/06/2024 11:12:52 AM
- Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition • GlobeNewswire Inc. • 11/01/2024 07:05:00 PM
- Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as R • GlobeNewswire Inc. • 11/01/2024 07:00:00 PM
- Teva Statement on European Commission Decision; Company to Appeal • GlobeNewswire Inc. • 10/31/2024 11:29:54 AM
- Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab) • GlobeNewswire Inc. • 10/22/2024 11:00:00 AM
- BP Signals Rising Net Debt; Tesla Slumps; Stellantis CEO Announces Retirement; Berkshire Trims BofA Stake, and More • IH Market News • 10/11/2024 10:31:49 AM
- Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA • GlobeNewswire Inc. • 10/08/2024 11:00:00 AM
- Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate • GlobeNewswire Inc. • 10/03/2024 12:30:00 PM
- Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S. • GlobeNewswire Inc. • 10/01/2024 12:29:04 PM
UAV Corp Skyborne Technology Secures $105M in Sales Contract LOIs for Revolutionary DART Series Airships • UMAV • Jan 13, 2025 11:00 AM
SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter 2024 (Ended December 31, 2024) • SNWV • Jan 13, 2025 8:10 AM
SANUWAVE Health Appoints Industry Veteran Timothy Wern as Executive Vice President of Sales • SNWV • Jan 13, 2025 8:08 AM
North Bay Resources Announces Operation of New Gravity Circuit at Bishop Gold Mill, California • NBRI • Jan 10, 2025 8:29 AM
Cannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology • BLO • Jan 9, 2025 8:49 AM
UAV Corp. (UMAV) Further Reduces Authorized Shares to 500 Million • UMAV • Jan 8, 2025 2:27 PM